Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results.

Coward, Jermaine I; Barve, Minal A; Kichenadasse, Ganessan; Moore, Kathleen N; Harnett, Paul R; Berg, Daniel; Garner, James S; Dizon, Don S

Coward, Jermaine I; Barve, Minal A; Kichenadasse, Ganessan; Moore, Kathleen N; Harnett, Paul R; Berg, Daniel; Garner, James S; Dizon, Don S.

Afiliação

Coward JI; ICON Cancer Centre, South Brisbane, QLD 4101, Australia.
Barve MA; School of Medicine, University of Queensland, Brisbane, QLD 4072, Australia.
Kichenadasse G; Mary Crowley Cancer Research Center, Dallas, TX 75251, USA.
Moore KN; Flinders Medical Centre, Adelaide, SA 5042, Australia.
Harnett PR; Department of Gynecologic Oncology, University of Oklahoma Health Science Center, Stephenson Cancer Center, Oklahoma City, OK 73104, USA.
Berg D; Crown Princess Mary Cancer Centre, Westmead, NSW 2145, Australia.
Garner JS; Formerly of Kazia Therapeutics Ltd., Sydney, NSW 2000, Australia.
Dizon DS; Kazia Therapeutics Ltd., Sydney, NSW 2000, Australia.

Cancers (Basel) ; 13(13)2021 Jun 26.

Article em En | MEDLINE | ID: mdl-34206826

Palavras-chave

intraperitoneal delivery; ovarian cancer; phase I; platinum refractory; platinum resistant

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google